Oct 27, 2009 0
Fish & Richardson Wins Ruling Barring Generic Versions of Allergan Glaucoma Drug
The glaucoma drug Alphagan P is responsible for about $240 million in annual revenue for the pharmaceutical company Allergan. So it’s no surprise that when Apotex and Exela Pharmsci told the Food and Drug Administration that they wanted to make generic versions of the drug, Allergan and its lawyers at Fish & Richardson filed patent infringement suits to stop them.




